Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

AbbVie

Eli Lilly

Merck

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.

4 Large Drug Stocks to Hold on to Amid Industry Challenges

Novo Nordisk stock: The weight-loss drug leader hit a buy point in the recent stock market rebound and is one of the best stocks to watch.

Weight Loss Leader Novo Nordisk Hits Buy Trigger In Stock Market Rebound

Novo Nordisk's Articles of Association, April 2024 Attachment Articles of Association 24 Apr 2024

Novo Nordisk A/S - Articles of Association, April 2024

Bagsværd, Denmark, 24 April 2024 – At Novo Nordisk's Annual General Meeting on 21 March 2024, it was decided to reduce the company's B share capital from DKK 343,512,800 to DKK 339,012,800 by cancellation of part of the company's portfolio of own B shares equal to a nominal value of DKK 4,500,000 divided into 45,000,000 B shares of DKK 0.10 each.

Novo Nordisk A/S – Reduction of the share capital

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?

The Wegovy and Ozempic maker continues to buy its own shares. It purchased more than 200,000 of them last week.

Why Novo Nordisk Topped the Market Today

NVO continues to be rated as a Buy, with the stock already charting an impressive +16.1% rally over the past three months, well outperforming the wider market at +4.8%. The management recently announced multiple expansions in its manufacturing/fill finish capacities, with the ongoing shortages still implying immense consumer demand. We believe that these capex will eventually be accretive to NVO's top/bottom lines, especially since the PFE CEO, Albert Bourla, has estimated an obesity market size of up $150B.

Novo Nordisk Remains The Better Buy After A Moderate Pullback

Altimmune

GoodRx Holdings

Viking Therapeutics

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

Vertex Pharmaceuticals

Great pharma companies tend to be entrenched in lucrative markets. Vertex Pharmaceuticals is managing to diversify off a strong base.

2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever

Eli Lilly has crushed the S&P 500 over the last 12 months and could continue delivering outsized returns. Novo Nordisk's strong fundamentals and solid growth opportunities make it a no-brainer buy.

3 Relatively Safe Growth Stocks You Can Buy and Hold

Health Care Select Sector SPDR Fund

Biotech stocks offer the possibility of groundbreaking medical advancements alongside the potential for explosive growth. While the sector carries inherent risks, a select group of biotech companies possesses the potential to deliver substantial returns in the coming years.

3 Biotech Stocks Set to Double by 2028

Bristol-Myers

Intuitive Surgical

Healthcare stocks can be excellent choices for investors, offering a balance of safety and growth. Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk all have strong growth potential.

Got $500? 3 Healthcare Stocks to Buy and Hold Forever

ICON

MercadoLibre

Shin-Etsu Chemical Co Ltd

Taiwan Semiconductor Manufacturing

It is understandable for U.S. investors to be focused on the largest technology companies that have driven such strong performance for the S&P 500 over the past decade. But learning about strategies that give exposure beyond the U.S. large-cap benchmark can help you to lower portfolio-concentration risk while expanding your set of opportunities for long-term growth in the stock market.

Eight stock picks in AI, obesity drugs, e-commerce and other growth areas beyond the S&P 500

The German cartel office has approved a deal by Denmark's Novo Nordisk to purchase Cardior Pharmaceuticals, the regulator said in a statement on Thursday.

German watchdog approves Novo's acquisition of Cardior Pharmaceuticals

Amgen

AstraZeneca

Structure Therapeutics Inc

Pfizer

Sanofi

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

The future of the U.S. economy appears promising, with robust growth and strong corporate performance. This economic strength has propelled the stock market to record highs, signaling confidence in the economy's resilience.

3 Pharma Stocks That Are Money-Printing Machines in 2024

Ginkgo Bioworks Holdings

Novo Nordisk and Ginkgo Bioworks will work together on manufacturing. Producing more obesity and diabetes medicines is likely a priority.

Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.

A staggering $1 trillion could be the annual cost to the US healthcare system if 40% of Americans with obesity begin treatment with GLP-1 drugs at current prices, according to Dr Jonathan Gruber, the Ford Professor of Economics at the Massachusetts Institute of Technology (MIT). This figure, which rivals the entire budget of the Medicare programme, highlights the potential fiscal challenges posed by these promising yet costly treatments for obesity.

Novo Nordisk and Eli Lilly weight loss drugs may not be a silver bullet, but they have huge potential, says leading US bank

Ozempic usage for weight loss has gone viral, making it the highest revenue-generating drug for Novo Nordisk AV/S NYSE: NVO. Originally purposed for Type 2 diabetes, the skyrocketing off-label use for weight loss led Novo to create Wegovy, a stronger version of Ozempic (generic name: semaglutide) for obesity.

Novo Nordisk Arms Wegovy to Be a Triple Threat

NVIDIA

Ares Management

Cameco

Saia

Nvidia, which bucked the S&P 500 downdraft last week, leads this weekend's watch list of five stocks near buy points.

Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level

BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S NVO after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and diabetes drugs.

Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating - Novo Nordisk (NYSE:NVO)

There is no evidence linking diabetes and weight loss drugs like Ozempic and Wegovy to an increase in suicidal thoughts, the European Union's drug regulator said Friday, the latest findings casting doubt on a link after a probe by U.S. regulators said a “small risk” couldn't be ruled out.

No Evidence Linking Ozempic And Suicidal Thoughts, EU Says

The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro.

EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts

Novo Nordisk and Eli Lilly & Co., the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months, BMO Capital Markets analysts said Friday.

Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say

A committee of the European Medicines Agency said Friday that a popular weight-loss drug doesn't increase the risk of suicide.

Popular weight-loss drug doesn't increase suicide risk, EU regulator says

News for Novo Nordisk Stock (NVO)